The GLP-1 Revolution Explained by a Doctor Running 20+ Pharma Trials
Episode description
Dr. Tom Elliott has spent more than four decades at the forefront of diabetes, endocrinology, and metabolic health.
He is the founder and medical director of BC Diabetes, an associate professor at UBC, and has been involved in more than 20 pharmaceutical clinical trials exploring the future of obesity, diabetes, and GLP-1 therapies. In this episode, Dr. Elliott breaks down why obesity, insulin resistance, and prediabetes have exploded across modern society, and why many founders and high performers are quietly damaging their metabolic health through stress, poor sleep, alcohol, sedentary work, and overstimulation.
We explore the science behind Ozempic, GLP-1 agonists, retatrutide, testosterone decline, fertility, fasting, aging, addiction, and the future of preventative medicine. Dr. Elliott also explains why some patients in clinical trials “begged to stop” after losing too much weight, and how these drugs may extend far beyond weight loss into addiction recovery and longevity research.
You will learn:
Why more than 150 million Americans may be prediabetic
What GLP-1 drugs actually do inside the body
Why Ozempic is affecting fertility, appetite, and addiction
How stress and sleep deprivation damage metabolism
Why muscle mass and strength matter as you age
The relationship between testosterone, aging, and performance
How modern food environments accelerate obesity and insulin resistance
This is a wide-ranging conversation on diabetes, longevity, performance, and the future of human health with one of Canada’s leading endocrinologists.